tesaglitazar has been researched along with Body Weight in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bakhti, M; Bastidas-Ponce, A; Baugé, E; Campbell, JE; Capozzi, M; Clemmensen, C; Collden, G; Cota, P; DiMarchi, RD; Douros, J; Drucker, DJ; DuBois, B; Feuchtinger, A; Finan, B; Garcia-Caceres, C; Grandl, G; Harger, A; Hennuyer, N; Herzig, S; Hofmann, SM; Klingelhuber, F; Knerr, PJ; Krahmer, N; Kulaj, K; Lalloyer, F; Lickert, H; Liskiewicz, A; Liskiewicz, D; Maity, G; Müller, TD; Novikoff, A; Perez-Tilve, D; Prakash, S; Quarta, C; Sanchez-Garrido, MA; Staels, B; Stemmer, K; Tschöp, MH; Yang, B; Zhang, Q | 1 |
1 other study(ies) available for tesaglitazar and Body Weight
Article | Year |
---|---|
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice.
Topics: Alkanesulfonates; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Male; Mice; Obesity; Phenylpropionates; PPAR alpha | 2022 |